Abstract: The present invention relates to the use of anti-CD3 and anti-CD25 antibodies for the management and treatment of inflammatory diseases and psycho-immune disorders, such as depression, autism (ASD) and attention deficit/hyperactivity disorder (ADHD). In one aspect, the invention concerns an antibody or fragment thereof, capable of binding to CD3 and/or CD25. In another aspect, the invention concerns a pharmaceutical composition comprising an antibody or fragment thereof according to the invention and an excipient, such as a pharmaceutically acceptable carrier. Other aspects of the invention are also disclosed.

Abstract: The present invention relates to vaccine compositions comprising lipid antigens, antibodies targeting lipid antigens, pharmaceutical compositions comprising such and their use in diagnosing, monitoring, treating, and preventing infectious disease, such as Lyme disease. In one aspect, administered is a therapeutically effective amount of a vaccine composition comprising a lipid antigen, an antibody or fragment thereof binding a lipid antigen, and/or a pharmaceutical composition comprising an antibody or fragment thereof binding a lipid antigen. Other aspects are described.

Abstract: The present invention inter alia relates to the use of phosphotidylserine or pathogenic sugar targeted therapeutics for the management and treatment of microbial infections, including Zika, Dengue, West Nile, Ebola, H1N1, enteroviruses, Leishmaniasis, Malaria and Coronaviruses SARS-COV. In an aspect, the invention concerns a fusion construct comprising an Ig-Fc domain or other protein scaffold, such as albumin, and a peptide, protein, or antibody fragment binding to phosphatidylserine and/or a peptide or protein binding to and/or recognizing a PAMP expressed by a microbe. Other aspects are described.

Abstract: The present invention relates to humanized antibodies and antigen binding fragments. More specifically, the invention relates to humanized antibodies and antigen binding fragment, capable of binding to antigens, wherein said antibodies or antigen binding fragments comprises at least 50% amino acids that are identical to the amino acids of the human germline of said antibody or antigen binding fragment. The present invention further relates to antibodies with minimal potential for immunogenicity by intraperitoneal or systemic administration to treat B7-H3(+) solid tumors. The invention further relates to fully humanized antibodies against B7-H3 with high human content, strong binding to B7-H3, high stability, high purity, and high expression titers.

Abstract: The present invention relates to B7H3-antibodies conjugated to specific chelators for radiolabeling with imaging or therapeutic radioisotopes. The invention further relates to B7H3-antibodies for treatment or theranostic use in cancer.

Abstract: The present invention relates to the use of phosphotidylserine or pathogenic sugar targeted therapeutics for the management and treatment of microbial infections, including Zika, Dengue, West Nile, Ebola, H1N1, enteroviruses, Leishmaniasis, Malaria and Coronaviruses SARS-COV.

Abstract: The present invention relates to the use of anti-CD3 and anti-CD25 antibodies for the management and treatment of inflammatory diseases and psycho-immune disorders, such as depression, autism (ASD) and attention deficit/hyperactivity disorder (ADHD).